65,437 trials
Asymptomatic Multiple Myeloma
Primary: Increase in ENK (Expanded Natural Killer Cells) Cells 7 Days After Treatment — 0 Participants
Non PTSD · PTSD
Primary: Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose — 3.78; 3.76; 3.52; 3.36 Z values — p=<0.001
Tetanus · Diphtheria · Haemophilus Influenzae Type b
Primary: Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP) — 126; 123; 130 Participants
Hemophagocytic Lymphohistiocytosis · X-Linked Lymphoproliferative Disorders · Chediak-Higashi Syndrome
Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds
Claustrophobia · Complication of Diagnostic Procedure
Primary: Change in Non-completion Rate of MRI Scans From the Average of the Baseline Year to the Average of One Year Post Training (All Scheduled Patients) — 10; -3.3 Percentage…
Environmental Exposure · Exposure to Pollution
Primary: Amount of Diethylhexyl Phthalate Removed From Hand — 94.64; 8.74 percentage of DEHP removed
PTSD
Primary: CAPS - PTSD Symptom Severity Score — 71.3; 72.5 units on a scale
Type 2 Diabetes Mellitus
Primary: Absolute Change From Baseline in HbA1c at Week 24 (DAO) — -0.82; -0.78 % (HbA1c) — p=0.6236
Alcohol Abuse · Tobacco Use Disorder · Marijuana Abuse
Primary: Days Per Month of Primary Substance Use — 23.2; 23.7; 24.2; 19.3 days per month — p=<0.001
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 2; 0; 1; 2 participants
Metastatic Breast Cancer
Primary: Progression-free Survival — 43 months
Multiple Myeloma
Primary: Phase 1: Percentage of Participants With Overall Response Rate (ORR) — 100.0; 100.0; 75.0; 66.7 Percentage of participants
Bipolar Disorder
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -8.91; -15.02 score on a scale — p=<0.0001
Ovarian Neoplasms
Primary: Progression-Free Survival (PFS) — 18.1; 17.3 weeks — p=0.8049